Imagion has released the Quarterly Activity Report and Appendix 4C for the period ending on 31 March 2022. The announcement highlights: MagSense® HER2 breast cancer
We are pleased to provide our investors with our April 2022 Investor Newsletter. In this edition, our Chief Financial Officer, Geoff Hollis, gives a recap
Imagion Biosystems Limited (ASX: IBX) is pleased to provide an update on the progress of its first-in-human study for the MagSense® HER2 breast cancer imaging
Imagion Biosystems has released its Annual Report for the year ended 31 December 2021. See linked documents below. 2021 Clinical Highlights: Multiple patients enrolled and
Imagion has released the Quarterly Activity Report and Appendix 4C for the period ending on 31 December 2021. The announcement highlights a recap of the
The document “Application for quotation of +securities” was lodged with ASX on 6th January, 2022. Please click to review the full announcement at ASX.
The document “Notice Pursuant to Section 708A(5)(e) of the Corporations Act 2001” was lodged with ASX on 6th January, 2022. Please click to review the
Tim Boreham revisits Imagion Biosystems’ potential in this 5-1/2 page article profiling the company and discussing its recent milestones. Read the article here.
The document “Notification of Issue, Conversion of Payment up of Unquoted Equity +Securities” was lodged with ASX on 16 December, 2021. Please click to review
The document “Remuneration Update and Employee Equity Incentives” was lodged with ASX on 16 December 2021. Please click to review the full announcement at ASX.
Imagion Biosystems (IBX) is an innovative medical imaging company that uses bio-safe magnetic nanoparticles to detect cancer and other diseases.
Stay informed about our latest news and developments.
© Imagion Biosystems, Ltd. All Rights Reserved | Privacy Policy | Terms & Conditions | Careers | Corporate Governance